Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by GoldenDilemmaon Mar 15, 2016 12:04pm
69 Views
Post# 24660055

RE:RE:Tribute Shares now worth 75c

RE:RE:Tribute Shares now worth 75cI am confident in Adams' ability. There do not appear to be any blatant red flags with fundamentals.

i also feel it is unjustified to bash Harris or Adams for the price action. It's out of their control. If you look at this from the POZN shareholder perspective, Adams is the white knight. TRX shareholders are now apart of the ride.

But, let's not forget that the major catalyst here is something POZN shareholders have been hoping for year to come. Yosprala is too far out for some exuberant price action especially considering market sentiment. 



<< Previous
Bullboard Posts
Next >>